Bausch + Lomb said it authorized management and advisers to explore a potential sale of the eye health company after shares dropped over reports of faltering deal talks with a group of private ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...

Bausch and Lomb rewards visa is a scam. I used the visa before the expiration date. The product was the wrong product. The retailer refunded the purchase price to the rewards card (in violation of ...

VAUGHAN, ON — Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit ...

Canada-headquartered Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company ... Although there is currently no cure for glaucoma, early intervention – including ...

A longtime Rochester company could potentially get a different owner. Bausch + Lomb, whose roots in Rochester date back to the 19 th century, confirmed this week that it may explore a potential ...